Moscow [Russia], November 13 (ANI/Sputnik): The production of the Favipiravir antiviral drug that will be used in COVID-19 vaccines will commence in December, the press service of the Russian pharmaceutical company Promomed told Sputnik.

"Production will start in December," a Promomed spokesperson said.

Also Read | PM Narendra Modi Meets US Congressional Delegation, Discusses Bilateral Issues.

On November 12, the drug was registered as a means to treat COVID-19 through vaccinations. It will be put into circulation for the next 5 years.

The drug was approved by Russia's health ministry to be developed into pills in 2020 and sold under the name of Areplivir to treat COVID-19 infections. Its chemical base was initially developed by Japanese company Fujifilm Holdings Corp as an influenza drug. (ANI/Sputnik)

Also Read | Guru Nanak Jayanti 2021: Pakistan Issues Visas to 3,000 Sikh Pilgrims From India For 552nd Birth Anniversary Celebrations of First Sikh Guru.

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)